PRECISE v2 and AI Role in MRI Prostate Cancer Surveillance Reviewed

A new review details PRECISE v2 refinements for prostate MRI active surveillance reporting, including minimum quality thresholds and disease visibility sub-groups. AI shows near-term promise for quality control and lesion tracking, but requires external validation before alterin…

• PRECISE v2 introduces minimum image quality thresholds (PRECISE-X), mandatory comparison with baseline and prior scans, and subdivides stable exams into visible (3-V) and non-visible (3-NonV) disease.
• Integration of artificial intelligence can apply automated quality checks, reduce measurement variability via segmentation, and combine imaging changes with clinical data like PSA density and kinetics for risk-adapted decision support.
• Critical barriers to clinical AI adoption in this setting include dataset shift, imperfect progression labels, lack of external validation, radiomic instability, and the need for transparent human-AI interaction.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.